Breaking: Novo set to close $16.5 billion Catalent deal

U.S. regulators declined to challenge the Novo Holdings-Catalent deal following months of scrutiny

Log In    Subscribe BREAKING NEWS   Novo Holdings is set to close its $16.5 billion acquisition of Catalent after FTC declines to challenge the deal By Ed Silverman Adobe Novo Holdings, the parent company of Novo Nordisk, is set to close its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge the deal following months of scrutiny.   Catalent is a major contract drug manufacturer and already helps manufacture Novo Nordisk's obesity drug Wegovy. The prospect that Novo Holdings would control one of the biggest players in pharmaceutical contract work prompted plenty of questions, but it didn't derail the deal. READ MORE Be the first to know Get instant notifications for the topics and reporters you choose with STAT+ Email Alerts. In Case You Missed It 1   Here are the 150 weight loss drugs in development to catch a booming market By Elaine Chen, Allison DeAngelis, and J. Emory Parker 2   Medicare moves to expand coverage for weight loss drugs Wegovy, Zepbound By Rachel Cohrs Zhang 3   Eli Lilly to test obesity medications as treatments for alcohol and drug addiction, CEO says By Elaine Chen 4   Catalent tries to reassure customers about its deal with Novo Holdings By Ed Silverman Don't miss out on another STAT Investigation Unlock the world of health and medicine with a subscription to STAT+ Learn more STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us